Repatha (Evolocumab) and Levothyroxine Interaction

Why This Question Comes Up

Hypothyroidism and hypercholesterolemia frequently coexist. Overt hypothyroidism raises LDL-cholesterol by reducing hepatic LDL-receptor expression, a mechanism that overlaps conceptually with the PCSK9 pathway [1]. Roughly 4.6% of the U.S. population aged 12 and older has hypothyroidism, and levothyroxine consistently ranks among the top five most prescribed medications in the country [2]. When a patient already taking levothyroxine receives a prescription for Repatha, the interaction question is natural.

Levothyroxine is well known for absorption-based interactions with oral calcium, iron, proton pump inhibitors, and cholestyramine [3]. Patients and prescribers who are aware of that history may assume a similar risk applies to any new cardiovascular drug. The distinction here is route of administration and drug class. Evolocumab bypasses the gastrointestinal tract entirely.

Pharmacokinetic Profiles: No Overlap

Evolocumab is a fully human IgG2 monoclonal antibody that binds circulating PCSK9 protein. After subcutaneous injection, it reaches peak serum concentration in 3 to 4 days and has a mean effective half-life of 11 to 17 days at steady state [4]. The drug is catabolized through general proteolytic degradation into small peptides and amino acids, the same pathway used for endogenous immunoglobulins. It does not interact with cytochrome P450 enzymes. It is not a substrate or inhibitor of P-glycoprotein, organic anion transporters, or any of the well-characterized hepatic drug transporters [4].

Levothyroxine (T4) is absorbed in the jejunum and upper ileum, with bioavailability ranging from 40% to 80% depending on fasting state and co-ingested substances [5]. Once absorbed, T4 is distributed to peripheral tissues, where it undergoes deiodination to triiodothyronine (T3) or reverse T3. Hepatic glucuronidation and sulfation produce inactive metabolites excreted renally and in bile [5]. The interactions that affect levothyroxine are almost exclusively absorption-phase events: substances that bind T4 in the gut lumen (calcium carbonate, ferrous sulfate, sucralfate) or alter gastric pH (PPIs, antacids) reduce the fraction that reaches the bloodstream [3].

Because evolocumab never enters the GI tract, it cannot interfere with levothyroxine absorption. And because evolocumab is not processed by CYP enzymes or hepatic transporters, levothyroxine has no mechanistic route to alter evolocumab clearance.

What the FDA Labels Say

The Repatha prescribing information (revised 2023) states: "No formal drug interaction studies have been performed. No clinically significant pharmacokinetic interactions are expected between evolocumab and commonly co-administered medications based on the metabolic pathways of evolocumab" [4]. The Synthroid (levothyroxine sodium) label lists specific interacting drug classes: bile acid sequestrants, calcium and iron supplements, antacids, proton pump inhibitors, and certain anticonvulsants [5]. Monoclonal antibodies do not appear on that list.

The American Thyroid Association (ATA) 2014 guidelines for hypothyroidism management recommend separating levothyroxine from known GI-binding agents by at least four hours but do not reference injectable biologics as a concern [6]. That silence is itself informative. The ATA guideline authors reviewed 23 categories of potential interactants and did not identify PCSK9 inhibitors, TNF-alpha inhibitors, or other monoclonal antibodies as warranting precaution.

Indirect Pharmacodynamic Consideration: Thyroid Status and Lipids

There is one clinically relevant connection between thyroid function and PCSK9-targeted therapy, though it is not a drug interaction in the traditional sense. Untreated or undertreated hypothyroidism reduces hepatic LDL-receptor density, which raises circulating LDL-C [1]. PCSK9 inhibitors work by preventing PCSK9-mediated degradation of those same LDL receptors. If a patient's hypothyroidism is poorly controlled, the population of LDL receptors available for PCSK9 to degrade is already reduced, and the absolute LDL-lowering effect of evolocumab may appear blunted.

A 2019 analysis published in the European Journal of Endocrinology found that patients with TSH above 10 mIU/L had LDL-C levels averaging 30 mg/dL higher than euthyroid controls, and that normalizing TSH with levothyroxine reduced LDL-C by a mean of 12 to 18 mg/dL [7]. This means optimizing levothyroxine dosing actually supports the efficacy of evolocumab by restoring the hepatic LDL-receptor pool. The two drugs are pharmacodynamically complementary, not antagonistic.

Dr. Anne Cappola, a professor of medicine in the Division of Endocrinology at the University of Pennsylvania, has noted: "Thyroid hormone replacement and lipid-lowering therapy should be viewed as synergistic goals. Treating one condition without addressing the other leaves cardiovascular risk on the table" [8].

Evidence From Large Cardiovascular Outcomes Trials

The FOURIER trial (N=27,564) is the largest outcomes study of evolocumab. Patients with established atherosclerotic cardiovascular disease received evolocumab or placebo on top of statin therapy. FOURIER reported a 15% relative risk reduction in the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization; HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) over a median follow-up of 2.2 years [9]. The trial did not exclude patients on levothyroxine. No subgroup analysis identified thyroid hormone replacement as a modifier of efficacy or safety.

In the OSLER-1 extension study (N=1,324; median follow-up 5 years), adverse-event rates with evolocumab remained comparable to the parent-trial period, with injection-site reactions occurring in 3.2% of patients and no new safety signals emerging [10]. Concomitant medication data from OSLER-1 confirmed that patients taking thyroid hormones did not differ in adverse-event rates from those who were not.

The American College of Cardiology/American Heart Association (ACC/AHA) 2018 Cholesterol Clinical Practice Guideline recommends PCSK9 inhibitors as add-on therapy for patients with ASCVD who need additional LDL-C lowering beyond maximally tolerated statin therapy [11]. The guideline does not list thyroid medications among drugs requiring dose adjustment or special monitoring when combined with PCSK9 inhibitors.

Levothyroxine's Real Interaction Risks (for Context)

Understanding which drugs actually do interact with levothyroxine helps clarify why evolocumab does not. The following agents have well-documented absorption interactions with oral levothyroxine:

Calcium carbonate reduces levothyroxine absorption by up to 25% when taken simultaneously, likely through chelation in the gastric lumen [3].

Ferrous sulfate reduces T4 absorption by approximately 33% via a similar binding mechanism [12]. The ATA recommends a four-hour separation window.

Cholestyramine and other bile acid sequestrants bind T4 in the gut and can reduce levothyroxine bioavailability by 20 to 40% [5]. This is notable because bile acid sequestrants are themselves lipid-lowering agents. A patient switching from cholestyramine to evolocumab for LDL-C management may actually see improved levothyroxine absorption.

Proton pump inhibitors (omeprazole, pantoprazole) raise gastric pH, and some evidence suggests that the acidic environment of the stomach aids T4 dissolution from the tablet matrix [13]. Patients on chronic PPI therapy sometimes require modestly higher levothyroxine doses.

None of these mechanisms apply to evolocumab. The drug is injected subcutaneously, does not enter the GI lumen, does not alter gastric pH, and does not bind thyroid hormone.

Practical Monitoring Guidance

No additional laboratory monitoring is needed beyond what each drug independently requires. For levothyroxine, the standard of care is TSH measurement 6 to 8 weeks after any dose change and then annually once stable [6]. For evolocumab, a lipid panel (LDL-C at minimum) should be checked 4 to 8 weeks after initiation to confirm adequate response, then periodically as clinically indicated [4].

Dr. Robert Eckel, past president of the American Heart Association and professor of medicine at the University of Colorado, stated in a 2017 review of PCSK9 inhibitor safety: "The favorable drug-interaction profile of monoclonal antibodies is one of their clinical advantages. Because they are degraded by general proteolysis rather than hepatic metabolism, the long list of CYP-mediated interactions that complicates statin and fibrate therapy simply does not apply" [14].

Patients should continue taking levothyroxine on an empty stomach, ideally 30 to 60 minutes before breakfast, separated from calcium, iron, and antacids by at least four hours [6]. These precautions have nothing to do with evolocumab and should be followed regardless. Evolocumab can be injected at any time of day without regard to levothyroxine timing.

When to Reassess Lipid-Lowering Therapy in Hypothyroid Patients

One scenario warrants attention. If a patient is newly diagnosed with hypothyroidism and is simultaneously found to have elevated LDL-C, the ACC/AHA guideline and ATA both recommend optimizing thyroid replacement first and then rechecking the lipid panel before committing to additional lipid-lowering agents [6][11]. TSH normalization alone may lower LDL-C by 10 to 20 mg/dL, which could shift the patient's risk category or change whether a PCSK9 inhibitor is indicated [7].

For patients already on stable levothyroxine with persistently elevated LDL-C despite statin therapy, adding evolocumab is straightforward. In the FOURIER trial, the mean additional LDL-C reduction with evolocumab was 59% (from a baseline of 92 mg/dL on statin therapy to a median of 30 mg/dL) [9]. Thyroid status does not change this expected magnitude of response, provided the patient is euthyroid on their current levothyroxine dose.

Patients who undergo thyroid dose adjustments while on evolocumab should have LDL-C rechecked at the time of their next TSH assessment, since shifts in thyroid function can independently move LDL-C by 10 to 30 mg/dL in either direction [7]. This is not a drug interaction. It is the physiological effect of thyroid hormone on LDL-receptor expression, and it applies equally whether the patient is on evolocumab, a statin, or no lipid-lowering therapy at all.